Quantcast

Contract Research Organization WCCT Global Announces Plan for Diabetes Ethnobridging Clinical Studies with the Advent of the Dramatic Rise of Type 2 Diabetes (T2DM) Prevalence in China

August 16, 2013

WCCT Global announces plan to help Chinese sponsors quickly start their ethnobridging clinical studies for diabetes research.

Costa Mesa, California (PRWEB) August 16, 2013

WCCT Global, a contract research organization headquartered in Southern California, announced a plan for diabetes ethnobridging clinical studies with a focus aimed to support China-based pharmaceutical companies. WCCT Global has been an industry leader in helping sponsors from Asia to initiate their new product development programs in the US. And now that China is becoming the country with the highest population of T2DM in the world, WCCT Global is placing an emphasis on supporting the Chinese Pharma Industry in the development of new T2DM drugs for China and exportation to other markets worldwide. WCCT Global has extensive research experience in both ethnobridging and T2DM clinical research and is the worldwide market leader in conducting ethnic sensitivity studies in various Asian populations.

WCCT Global is located in Southern California which is richly populated by many diverse populations. However, 17% of all Asian Americans are living in Southern California, making it the largest Asian population in the U.S. Therefore, WCCTG can reach out to Japanese, Chinese, Korean, Vietnamese, Philippine, and Taiwanese and screen large numbers for either healthy volunteer or patient studies. WCCT Global’s VP of Business Development Talia Nikolao stated, “Our capabilities in ethnobridging clinical studies is the reason why many of our clients come back time and time again to have WCCT Global conduct their clinical studies.”

More about WCCT Global:

WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH) as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you are interested in more information about WCCT Global's ethnobridging capabilities, click here.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/8/prweb11031645.htm


Source: prweb



comments powered by Disqus